Intranasal Administration of a Meningococcal Outer Membrane Vesicle Vaccine Induces Persistent Local Mucosal Antibodies and Serum Antibodies with Strong Bactericidal Activity in Humans

Infection and Immunity

Volumn 66, Issue 4, 1998, Pages 1334-1341

  Haneberg, Bjørn ^a   Dalseg, Rolf ^a   Wedege, Elisabeth ^a   Høiby, E Arne ^a   Haugen, Inger Lise ^a   Oftung, Fredrik ^a   Andersen, Svein Rune ^a   Næss, Lisbeth Meyer ^a   Aase, Audun ^a   Michaelsen, Terje E ^a   Holst, Johan ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; BACTERIUM ANTIBODY;

ADULT; ARTICLE; BIOSYNTHESIS; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; MUCOSAL IMMUNITY; NEISSERIA MENINGITIDIS;

ADMINISTRATION, INTRANASAL; ADULT; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNITY, MUCOSAL; MALE; MIDDLE AGED; NEISSERIA MENINGITIDIS;

EID: 0032038675     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.66.4.1334-1341.1998     Document Type: Article

References (31)

1. Aaberge, I. S., E.-C. Groeng, I. L. Haugen, R. Dalseg, M. Løvik, and B. Haneberg. 1995. Induction of systemic and mucosal antibodies to pneumococcal antigens by mucosal immunizations. J. Cell. Biochem. Suppl. 19A:242.
2. Aggerbeck, H., S. Gizurarson, J. Wantzin, and I. Heron. 1997. Intranasal booster vaccination against diphtheria and tetanus in man. Vaccine 15: 307-316.
3. Bergquist, C., T. Lagergård, and J. Holmgren. 1997. Anticarrier immunity suppresses the antibody response to polysaccharide antigens after intranasal immunization with the polysaccharide-protein conjugate. Infect. Immun. 65: 1579-1583.
4. Bergquist, C., E. L. Johansson, T. Lagergård, J. Holmgren, and A. Rudin. 1997. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect. Immun. 65:2676-2684.
5. Berstad, A. K. H., J. Holst, I. L. Haugen, B. Møgster, and B. Haneberg. 1997. A nasal whole-cell Bordetella pertussis vaccine can induce strong systemic and mucosal antibody responses which are not enhanced by cholera toxin. Vaccine 15:1473-1478.
6. Bjune, G., E. A. Høiby, J. K. Grønnesby, Ø. Arnesen, J. H. Fredriksen, A. Halstensen, E. Holten, A. K. Lindbak, H. Nøkleby, E. Rosenqvist, L. K. Solberg, O. Closs, J. Eng, L. O. Frøholm, A. Lystad, L. S. Bakketeig, and B. Hareide. 1991. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338:1093-1096.
7. Brandtzaeg, P. 1992. Humoral immune response patterns of human mucosa: induction and relation to bacterial respiratory infections. J. Infect. Dis. 165: s167-s176.
8. Dalseg, R., E. Wedege, I. L. Haugen, J. Holst, and B. Haneberg. 1995. Group B meningococcal OMV vaccine as a mucosal immunogen. Clin. Immunol. Immunopathol. 76:S93.
9. Dalseg, R., J. Holst, T. Tangen, G. Stabbetorp, P. Simonsen, E. Jantzen, B. Haneberg, E. Namork, and L. R. Haaheim. 1996. Outer membrane vesicles from group-B meningococci can act as mucosal adjuvant for influenza virus antigens, p. 177-182. In E. Brown, E. Norrby, D. Burton, and J. Mekalanos (ed.), Vaccines 96. Molecular approaches to the control of infectious diseases. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
10. Elson, C. O. 1996. Cholera toxin as a mucosal adjuvant, p. 59-72. In H. Kiyono, P. L. Ogra, and J. R. McGhee (ed.), Mucosal vaccines. Academic Press, San Diego, Calif.
11. Forrest, B. D. 1992. Effects of sample processing on the measurement of specific intestinal IgA immune responses. Vaccine 10:802-805.
12. Fredriksen, J. H., E. Rosenqvist, E. Wedege, K. Bryn, G. Bjune, L. O. Frøholm, A.-K. Lindbak, B. Møgster, E. Namork, U. Rye, G. Stabbetorp, R. Winsnes, B. Aase, and O. Closs. 1991. Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann. 14:67-80.
13. Haneberg, B., D. Kendall, H. M. Amerongen, F. M. Apter, J.-P. Kraehenbuhl, and M. R. Neutra. 1994. Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina measured by a new method for collection of secretions from local mucosal surfaces. Infect. Immun. 62: 15-23.
14. Høiby, E. A., E. Rosenqvist, L. O. Frøholm, G. Bjune, B. Feiring, H. Nøkleby, and E. Rønnild. 1991. Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey. NIPH Ann. 14:147-156.
15. Holmgren, J., and A.-M. Svennerholm. 1996. Oral vaccines against cholera and enterotoxigenic Escherichia coli diarrhea, p. 241-253. In H. Kiyono, P. L. Ogra, and J. R. McGhee (ed.), Mucosal vaccines. Academic Press, San Diego, Calif.
16. Hordnes, K., T. Tynning, T. A. Brown, B. Haneberg, and R. Jonsson. 1997. Nasal immunization with group B streptococci can induce high levels of specific IgA antibodies in cervicovaginal secretions of mice. Vaccine 15: 1244-1251.
17. Jarvis, G. A., and J. M. Griffiss. 1991. Human IgA1 blockade of IgG-initiated lysis of Neisseria meningitidis is a function of antigen-binding fragment binding to the polysaccharide capsule. J. Immunol. 147:1962-1967.
18. Moldoveanu, Z., M. L. Clements, S. J. Prince, B. R. Murphy, and J. Mestecky. 1995. Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine 13:1006-1012.
19. Neutra, M. R., A. Frey, and J.-P. Kraehenbuhl. 1996. Epithelial M cells: gateways for mucosal infection and immunization. Cell 86:345-348.
20. Perkins, B. A., K. Jonsdottir, H. Briem, E. Griffiths, B. D. Plikaytis, E. A. Høiby, E. Rosenqvist, J. Holst, H. Nøkleby, F. Sotolongo, G. Sierra, C. Huergo, G. M. Carlone, D. Williams, J. Dykes, D. Kapczynski, E. Tikhomirov, J. D. Wenger, and C. V. Broome. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J. Infect. Dis., in press.
21. Rosenqvist, E., E. A. Høiby, E. Wedege, B. Kusecek, and M. Achtmann. 1993. The 5c protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies. J. Infect. Dis. 167:1065-1073.
22. Rosenqvist, E., E. A. Høiby, E. Wedege, K. Bryn, J. Kolberg, A. Klem, E. Rønnild, G. Bjune, and H. Nøkleby. 1995. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect. Immun. 63:4642-4652.
23. Staats, H. F., and J. R. McGhee. 1996. Application of basic principles of mucosal immunity to vaccine development, p. 17-39. In H. Kiyono, P. L. Ogra, and J. R. McGhee (ed.), Mucosal vaccines. Academic Press, San Diego, Calif.
24. Walker, R. I. 1994. New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine 12:387-400.
25. Ward, R. L. 1996. Mechanism of protection against Rotavirus in humans and mice. J. Infect. Dis. 174:S51-S58.
26. Wedege, E., and L. O. Frøholm. 1986. Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting. Infect. Immun. 51:571-578.
27. Wedege, E., K. Bryn, and L. O. Frøholm. 1988. Restoration of antibody binding to blotted meningococcal outer membrane proteins using various detergents. J. Immunol. Methods 113:51-59.
28. Wedege, E., E. A. Høiby, E. Rosenqvist, and L. O. Frøholm. 1990. Serotyping and subtyping of Neisseria meningitidis isolated by co-agglutination dotblotting and ELISA. J. Med. Microbiol. 31:195-201.
29. Wedege, E., G. Bjune, L. O. Frøholm, E. A. Høiby, and E. Rosenqvist. 1991. Immunoblotting studies of vaccinee and patient sera from a Norwegian serogroup B meningococcal vaccination trial. NIPH Ann. 14:183-186.
30. Winther, B., and D. J. Innes. 1994. The human adenoids. A morphologic study. Arch. Otolaryngol. Head Neck Surg. 120:144-149.
31. Zollinger, W. D. 1991. Meningococcal meningitis, p. 113-126. In S. J. Cryz (ed.), Vaccines and immunotherapy. Pergamon Press, New York, N.Y.